Sandbox/v20: Difference between revisions
< Sandbox
Gerald Chi (talk | contribs) Created page with " ====Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin==== {| |- | valign=top | {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: lef..." |
Ahmed Zaghw (talk | contribs) No edit summary |
||
(4 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
{{Endocarditis}} | |||
<div class="mw-collapsible mw-collapsed"> | |||
<div class="mw-collapsible-content"> | |||
</div></div> | |||
<div class="mw-collapsible mw-collapsed"> | |||
====Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin==== | ====Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin==== | ||
<div class="mw-collapsible-content"> | |||
{| | {| | ||
|- | |- | ||
| valign=top | | | valign=top | | ||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width: | {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:35em" cellpadding="0" cellspacing="0"; | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Enterococcus Susceptible to <BR> Penicillin, Gentamicin, and Vancomycin}}'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Enterococcus Susceptible to <BR> Penicillin, Gentamicin, and Vancomycin}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen (Adult)'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h x 4—6 weeks''''' <BR> ''OR'' <BR> ▸ '''''[[Penicillin G potassium]] 3—5 million U/day IV q4h x 4—6 weeks''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 4—6 weeks''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen (Pediatric)'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h x 4—6 weeks''''' <BR> ''OR'' <BR> ▸ '''''[[Penicillin G potassium]] 3—5 million U/day IV q4h x 4—6 weeks''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 4—6 weeks''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Alternative Regimen (Adult)''<sup>†</sup> | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q12h x 6 weeks''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 6 weeks''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Alternative Regimen (Pediatric)''<sup>†</sup> | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q12h x 6 weeks''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 6 weeks''''' | ||
|- | |- | ||
|} | |} | ||
| valign=top | | | valign=top | | ||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width: | {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:38em" cellpadding="0" cellspacing="0"; | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age <50 Years}}<sup>†</sup>'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age <50 Years}}<sup>†</sup>'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age >50 Years}}'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age >50 Years}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Immunocompromised}}'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Immunocompromised}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h''''' <BR> ''OR'' <BR> ▸ '''''[[Meropenem]] 2 g IV q8h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Recurrent}}'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Recurrent}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30—60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h''''' | ||
|} | |} | ||
|} | |} | ||
< | </div></div> | ||
Latest revision as of 02:01, 16 January 2014
Endocarditis Microchapters |
Diagnosis |
---|
Treatment |
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease |
Case Studies |
Sandbox/v20 On the Web |
Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin
|
|